TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 ...
Sagimet Biosciences Inc. has obtained IND clearance from the FDA for TVB-3567 (ASC-60), a selective small-molecule fatty acid ...
Try Now>> See the top stocks recommended by analysts >> Sagimet Biosciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025Denifanstat received Breakthrough Therapy ...
HC Wainwright reaffirmed their buy rating on shares of Sagimet Biosciences (NASDAQ:SGMT – Free Report) in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $32.00 ...
Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.
Hosted on MSN2mon
Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug CandidateThe presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase 2b ...
Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback